Related Experiment Video

Updated: May 31, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia

Theodosios D Filippatos1, Moses S Elisaf

  • 1Department of Internal Medicine, University of Ioannina Medical School, Ioannina, Greece.

Expert Opinion on Pharmacotherapy
|July 9, 2011
PubMed

Insights

Fenofibrate plus simvastatin combination therapy effectively improves lipid profiles and reduces residual cardiovascular disease (CVD) risk in patients with atherogenic dyslipidaemia. Careful monitoring is essential for safety.

Area of Science:

  • Cardiology
  • Pharmacology
  • Lipidology

Background:

  • Statins significantly reduce cardiovascular disease (CVD) risk but leave residual risk.
  • Patients on optimal statin therapy may still experience CVD events.

Purpose of the Study:

  • To review evidence on fixed-dose fenofibrate plus simvastatin combination therapy.
  • To assess its efficacy and safety in managing mixed dyslipidaemia and residual CVD risk.

Main Methods:

  • Systematic review of studies indexed in Pubmed and Scopus.
  • Analysis of clinical trial data on fenofibrate-simvastatin combination therapy.
  • Evaluation of adverse events and clinical outcomes.

Main Results:

  • Combination therapy improves lipoprotein profiles in mixed dyslipidaemia.
  • Adverse event rates were comparable to monotherapy, but careful monitoring is advised.
  • The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study showed no significant reduction in CVD events versus simvastatin alone, but potential benefit in a subgroup with high triglycerides and low HDL cholesterol.

Conclusions:

  • Fixed-dose fenofibrate plus simvastatin offers additive benefits and is safe with proper monitoring.
  • This combination supports reducing residual CVD risk in patients with atherogenic dyslipidaemia.
  • Clinical outcomes did not improve without underlying dyslipidaemia.
Abstract

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Dosage Regimen: Fixed Dose01:01

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...